Brokerages Set HCP, Inc. (NYSE:HCP) PT at $36.78

HCP, Inc. (NYSE:HCP) has received an average recommendation of “Buy” from the twelve research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $36.78.

Several equities analysts recently issued reports on HCP shares. KeyCorp boosted their price target on HCP from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, October 2nd. Morgan Stanley boosted their price target on HCP from $32.00 to $35.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 17th. Scotiabank set a $38.00 price objective on HCP and gave the company a “buy” rating in a report on Monday, September 30th. JPMorgan Chase & Co. raised HCP from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $35.00 to $38.00 in a report on Tuesday, October 8th. Finally, Barclays lifted their price objective on HCP from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Wednesday, October 2nd.

Shares of HCP stock opened at $34.49 on Friday. The stock has a market capitalization of $17.02 billion, a PE ratio of 18.95, a price-to-earnings-growth ratio of 6.81 and a beta of 0.22. HCP has a 52-week low of $26.58 and a 52-week high of $37.93. The stock’s 50-day moving average price is $33.88 and its 200 day moving average price is $34.24. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.01.

HCP (NYSE:HCP) last issued its quarterly earnings results on Wednesday, October 30th. The real estate investment trust reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.43 by ($0.52). The company had revenue of $538.00 million during the quarter, compared to analyst estimates of $503.65 million. HCP had a net margin of 43.66% and a return on equity of 12.78%. The business’s revenue was up 18.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.44 EPS. Analysts expect that HCP will post 1.75 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Quest Capital Management Inc. ADV purchased a new stake in shares of HCP during the 3rd quarter worth approximately $28,000. Bartlett & Co. LLC purchased a new stake in shares of HCP during the 3rd quarter worth approximately $36,000. CSat Investment Advisory L.P. boosted its stake in shares of HCP by 77.6% during the 2nd quarter. CSat Investment Advisory L.P. now owns 1,165 shares of the real estate investment trust’s stock worth $37,000 after acquiring an additional 509 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of HCP by 29.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,364 shares of the real estate investment trust’s stock worth $49,000 after acquiring an additional 314 shares in the last quarter. Finally, North Star Investment Management Corp. purchased a new stake in shares of HCP during the 3rd quarter worth approximately $54,000. 95.80% of the stock is currently owned by institutional investors and hedge funds.

HCP Company Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Featured Article: How to identify percentage decliners

Analyst Recommendations for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.